FDA approves landmark pancreatic cancer drug that’s shown to improve survival
Researchers are investigating why the clinical benefits of daraxonrasib eventually fade, even as the recently cleared treatment extends life expectancy for pancreatic cancer patients. Approved by regulators in August as an oral targeted therapy for metastatic pancreatic adenocarcinoma, the once-daily pill nearly doubled survival rates in advanced cases. Developed jointly by Revolution Medicines and the Dana-Farber Cancer Institute, the medication targets specific RAS protein mutations that drive tumor growth. Scientists at Sylvester Comprehensive Cancer Center reported on the approval while examining how the drug impacts overall patient care.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Daraxonrasib was cleared by regulators in August as an oral targeted treatment for metastatic pancreatic adenocarcinoma.
- ✓ The once-daily pill targets specific RAS protein mutations that drive tumor growth.
- ✓ Clinical testing showed that the medication nearly doubled survival in advanced cases.
What changed
Researchers are now racing to determine why the therapeutic benefits of the newly approved pancreatic cancer drug daraxonrasib eventually fade over time.
Live updates
-
Researchers Race to Study Why Pancreatic Cancer Drug Daraxonrasib Fades
Researchers are investigating why the clinical benefits of daraxonrasib eventually fade, even as the recently cleared treatment extends life expectancy for pancreatic cancer patients. Approved by regulators in August as an oral targeted therapy for metastatic pancreatic adenocarcinoma, the once-daily pill nearly doubled survival rates in advanced cases. Developed jointly by Revolution Medicines and the Dana-Farber Cancer Institute, the medication targets specific RAS protein mutations that drive tumor growth. Scientists at Sylvester Comprehensive Cancer Center reported on the approval while examining how the drug impacts overall patient care.
Why it matters
Pancreatic cancer remains one of the most difficult malignancies to treat, making any therapy that extends life expectancy a major development for adult patients. The approval of daraxonrasib provides a new therapeutic option for individuals who underwent prior therapy or cannot tolerate multiagent regimens. Investigators are now racing to understand resistance mechanisms to maximize the longevity of the treatment benefit.
What is confirmed
- Daraxonrasib was cleared by regulators in August as an oral targeted treatment for metastatic pancreatic adenocarcinoma.
- The once-daily pill targets specific RAS protein mutations that drive tumor growth.
- Clinical testing showed that the medication nearly doubled survival in advanced cases.
Still unconfirmed
- Researchers are racing to figure out why the benefits provided by daraxonrasib fade over time.
What to watch next
- Further findings from Sylvester Comprehensive Cancer Center researchers regarding daraxonrasib resistance
- Additional studies on how the drug impacts long-term patient outcomes and overall care
confidence 100%Sources used for this update (3)
- www.newser.com — How a Promising Pancreatic Cancer Drug Loses Its Punch - Newser
- www.nbclosangeles.com — Missouri woman survives colon cancer 3 times, reveals major symptom – NBC Los Angeles
- Bioengineer.org — FDA Approval of Daraxonrasib Marks Turning Point in ...
-
FDA Approves Daraxonrasib for Advanced Pancreatic Cancer
The Food and Drug Administration approved daraxonrasib as an oral targeted treatment for metastatic pancreatic adenocarcinoma, adding a new therapeutic option for adult patients during the third quarter of 2026. Developed jointly by Revolution Medicines and the Dana-Farber Cancer Institute, the once-daily pill targets specific RAS protein mutations that drive tumor growth. Clinical testing previously demonstrated that the medication extends life expectancy and nearly doubled survival in advanced cases for patients who underwent prior therapy or cannot tolerate multiagent regimens. As clinicians celebrate the regulatory milestone, researchers continue to study how the drug impacts overall patient care and long-term outcomes.
Why it matters
Pancreatic cancer remains one of the most difficult malignancies to treat, historically offering limited survival gains for patients with advanced disease. The introduction of targeted oral therapies represents a shift away from traditional multiagent regimens that many vulnerable patients cannot tolerate. Regulatory bodies evaluated oncology treatments throughout the third quarter of 2026, granting early clearance based on trial data showing extended survival.
What is confirmed
- The Food and Drug Administration issued approvals for new treatment options for cancers of the pancreas in the third quarter of 2026.
- Daraxonrasib is an oral targeted treatment for metastatic pancreatic adenocarcinoma developed by Revolution Medicines and the Dana-Farber Cancer Institute.
Still unconfirmed
- Devalingam Mahalingam, MBBChBAO, PhD, states that the biggest question regarding daraxonrasib is whether researchers will ever find a cure.
What to watch next
- Additional patient care and research impact data from medical journals
- Further regulatory tracking of Revolution Medicines pipeline milestones and PDUFA dates
confidence 90%Sources used for this update (5)
- www.marketbeat.com — Revolution Medicines (RVMD) FDA Approvals, PDUFA Dates & Drug Alerts ...
- www.aacr.org — FDA Approvals in Oncology: July-September 2026 | Blog | AACR
- www.wral.com — AP Health News and Reporting Coverage, page 8 | WRAL
- www.wral.com — Business News and Reporting Coverage, page 34 | WRAL
- www.physiciansweekly.com — Q&A: Daraxonrasib's Impact on Pancreatic Cancer Research ...
-
FDA Approves Daraxonrasib for Advanced Pancreatic Cancer
The Food and Drug Administration granted approval for daraxonrasib, an oral targeted treatment for metastatic pancreatic adenocarcinoma. Developed by Revolution Medicines and the Dana-Farber Cancer Institute, the once-daily pill targets specific RAS protein mutations that drive tumor growth. Clinical testing demonstrated that the medication extends life expectancy and improves survival rates for adult patients who previously underwent therapy or cannot tolerate multiagent regimens. The regulatory decision arrived ahead of schedule, following trial data that showed the medication nearly doubled survival in advanced cases.
Why it matters
Pancreatic cancer remains one of the most difficult malignancies to treat, making the approval of a targeted oral option significant for patients with limited choices. The medication earned a rare standing ovation at ASCO 2026 after data indicated it nearly doubled survival in advanced disease. Medical professionals continue to evaluate how the drug will integrate into standard care protocols for pretreated metastatic pancreatic ductal adenocarcinoma.
What is confirmed
- The FDA approved daraxonrasib to treat metastatic pancreatic adenocarcinoma.
- The medication is an oral targeted treatment designed for adults facing advanced disease.
- Revolution Medicines and the Dana-Farber Cancer Institute developed the medication.
- The drug targets specific RAS protein mutations driving tumor growth.
Still unconfirmed
- Daraxonrasib nearly doubled survival in advanced pancreatic cancer and won a rare standing ovation at ASCO 2026.
What to watch next
- ASCO presentations detailing further clinical trial metrics for daraxonrasib
- Clinical adoption rates and real-world patient outcomes following the FDA approval
confidence 90%Sources used for this update (2)
- ftloscience.com — Rasonque (Daraxonrasib): The Pancreatic Cancer Pill Explained
- www.onclive.com — FDA Approval Insights: Daraxonrasib for Metastatic Pancreatic ...
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The Food and Drug Administration approved daraxonrasib to treat metastatic pancreatic adenocarcinoma. The medication is an oral targeted treatment designed for adults facing advanced disease. Clinical testing demonstrated that the once-daily pill extends life expectancy and improves survival rates for patients who previously underwent therapy or cannot tolerate multiagent regimens. Revolution Medicines and the Dana-Farber Cancer Institute developed the medication. The regulatory decision arrived ahead of schedule following trial data showing the drug targets specific RAS protein mutations driving tumor growth.
Why it matters
Targeting RAS protein mutations has represented a major scientific hurdle in oncology for decades due to the elusive nature of the driver. The approval follows a half century of basic science, public funding, and human persistence focused on unlocking treatments for one of the deadliest forms of cancer. Clinical trials evaluated the therapy in patients with advanced disease.
What is confirmed
- The Food and Drug Administration approved daraxonrasib, also known as Rasonque, as a first-in-class targeted oral treatment for adults with metastatic pancreatic adenocarcinoma.
- The once-daily pill targets specific RAS protein mutations that drive tumor growth.
- The regulatory decision arrived more than six months ahead of schedule following clinical data showing the drug can extend life expectancy and nearly double survival rates.
- Revolution Medicines and the Dana-Farber Cancer Institute developed the medication.
Still unconfirmed
- The Christ Hospital Health Network enrolled the second ever patient in the clinical trial.
What to watch next
- Commercial availability and patient access timelines for Rasonque
- Post-market clinical data regarding long-term survival outcomes in broader patient populations
confidence 100%Sources used for this update (2)
- www.thechristhospital.com — FDA Approves Pancreatic Cancer Drug | The Christ Hospital
- www.medscape.com — How Scientists Finally Cracked RAS in Pancreatic Cancer - Today on Medscape
-
FDA Approves Daraxonrasib for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration approved daraxonrasib, also known as Rasonque, as a first-in-class targeted oral treatment for adults with metastatic pancreatic adenocarcinoma. Developed by Revolution Medicines and the Dana-Farber Cancer Institute, the once-daily pill targets specific RAS protein mutations that drive tumor growth. The regulatory decision arrived more than six months ahead of schedule following clinical data showing the drug can extend life expectancy and nearly double survival rates for patients with advanced disease who received prior therapy or cannot take multiagent regimens.
Why it matters
Pancreatic cancer stands as the third deadliest cancer in the United States, and patients typically face late diagnoses. Daraxonrasib marks the first approved targeted therapy for this condition, addressing a major driver of tumor growth that previously lacked effective broad treatments. Meanwhile, international regulatory discussions continue as lawmakers debate oversight of foreign-funded medicine imports.
What is confirmed
- The U.S. Food and Drug Administration approved Revolution Medicines' Rasonque, also known as daraxonrasib, on August 26, 2026.
- Daraxonrasib is indicated for adults with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
- The medication is an oral first-in-class RAS(ON) inhibitor that targets multiple forms of the RAS protein to block abnormal cell growth.
- The Christ Hospital Health Network enrolled the second ever patient in the clinical trial for daraxonrasib.
What to watch next
- Additional survival data from the RASolute 302 trial presented by medical experts.
- Broader clinical rollout and availability of daraxonrasib for patients across hospital networks.
confidence 100%Sources used for this update (13)
- article.wn.com — FDA Approves Drug for Pancreatic Cancer Following ...
- www.fda.gov — U.S. Food and Drug Administration
- www.fda.gov — Drugs | FDA
- www.myjoyonline.com — ‘We shouldn’t allow their drugs in just because they’re giving us $100m’ – Dr Nawaane - MyJoyOn....
- en.wikipedia.org — Food and Drug Administration - Wikipedia
- www.usa.gov — Food and Drug Administration (FDA) | USAGov
- www.fda.gov — Food and Drug Administration | FDA
- www.fda.gov — What We Do | FDA
- www.wbur.org — How an Mass. researcher's lab made a breakthrough in pancreatic cancer treatment
- www.onclive.com — Daraxonrasib Approval Signals a New Era for RAS-Targeted ...
- www.fox8live.com — FDA approves new pill for pancreatic cancer treatment
- gizmodo.com — This Pill Will Change Cancer Treatment Forever - Gizmodo
-
FDA Approves Daraxonrasib for Pancreatic Cancer
The FDA has approved daraxonrasib, also known as Rasonque, for treating adults with metastatic pancreatic adenocarcinoma. Clinical data suggests the treatment can nearly double survival rates for those with this advanced disease. Developed by RevMed as an oral multi-selective RAS(ON) inhibitor, the medication targets specific cancer cells.
Why it matters
Pancreatic cancer is a highly aggressive and often fatal disease, with limited treatment options for patients with advanced stages. The approval of daraxonrasib offers new hope for these patients. The drug's unique mechanism of action, targeting RAS proteins, sets it apart from existing treatments.
What is confirmed
- The FDA has approved daraxonrasib for treating adults with metastatic pancreatic adenocarcinoma.
- Daraxonrasib, also known as Rasonque, was developed by RevMed as an oral multi-selective RAS(ON) inhibitor.
Still unconfirmed
- Early findings indicate the drug may also combat treatment-resistant lung cancer.
What to watch next
- The presentation of data from Merck and Moderna's Phase 3 INTerpath-001 trial on intismeran autogene in combination with KEYTRUDA.
- Further testing of Propanc Biopharma's complementary mechanism to deepen responses to RAS inhibitors like those from Revolution Medicines.
confidence 90%Sources used for this update (2)
- www.wmur.com — FDA panel endorses first-of-a-kind cancer blood test
- www.merck.com — Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoin....
-
FDA-approved daraxonrasib shows potential for lung cancer treatment
The FDA-approved pancreatic cancer drug daraxonrasib, also known as Rasonque, is showing promise in early trials for treating lung cancer. Developed by RevMed as an oral multi-selective RAS(ON) inhibitor, the medication targets adults with metastatic pancreatic adenocarcinoma. Clinical data suggests the treatment can nearly double survival rates for those with this advanced disease. While primarily authorized for pancreatic cancer, early findings indicate the drug may also combat treatment-resistant lung cancer. Propanc Biopharma is currently testing a complementary mechanism to deepen responses to RAS inhibitors like those from Revolution Medicines.
Why it matters
Pancreatic cancer is typically detected in its latest stages, making it difficult to treat. Daraxonrasib provides a new therapeutic option for metastatic cases where survival rates were previously lower. The expansion into lung cancer trials suggests a broader application for RAS(ON) inhibitors.
What is confirmed
- Daraxonrasib is an oral multi-selective RAS(ON) inhibitor developed by RevMed.
- The FDA authorized daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- Clinical data shows the drug can nearly double survival rates for individuals with metastatic pancreatic adenocarcinoma.
Still unconfirmed
- Daraxonrasib may help fight treatment-resistant lung cancer.
- Propanc Biopharma's PRP mechanism showed over 90% tumor-growth inhibition and over 2.5-fold survival benefit in preclinical PDAC data.
What to watch next
- Results from lung cancer clinical trials for daraxonrasib
- Clinical trial data for Propanc Biopharma's PRP complementary therapy
confidence 90%Sources used for this update (4)
- www.medicalnewstoday.com — Pancreatic cancer drug may also help fight treatment-resistant lung cancer
- finance.yahoo.com — Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
- www.scientificamerican.com — Blood test shows promise in detecting pancreatic cancer early—a 'Holy Grail' for the field
- finance.yahoo.com — Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
-
FDA Approves Daily Pill for Advanced Pancreatic Cancer
The Food and Drug Administration recently authorized a daily pill designed to treat pancreatic cancer patients. The medication targets adults diagnosed with metastatic pancreatic adenocarcinoma and is produced as an oral multi-selective RAS(ON) inhibitor developed by RevMed, known as daraxonrasib. Clinical data indicates the treatment can nearly double survival rates for individuals with this advanced form of the disease. Former University of Florida President Sasse and other patients have credited the medication with extending their lives. Early study findings also suggest potential benefits for lung cancer patients.
Why it matters
Pancreatic cancer remains one of the most challenging malignancies to treat, making targeted therapies a critical advancement for patients. Daraxonrasib represents a new approach by utilizing an oral multi-selective RAS(ON) inhibitor. The Food and Drug Administration authorization offers a daily pill option for individuals battling metastatic pancreatic adenocarcinoma.
What is confirmed
- The Food and Drug Administration approved a new daily pill drug for pancreatic cancer patients.
- The medication daraxonrasib is an oral multi-selective RAS(ON) inhibitor developed by RevMed.
- The drug was authorized for adults diagnosed with metastatic pancreatic adenocarcinoma.
- Clinical data shows the medication can nearly double survival rates for patients with this disease.
- Patients including former University of Florida President Sasse have credited the drug with extending their lives.
Still unconfirmed
- Early study findings indicate the medication may also offer potential benefits for lung cancer patients.
What to watch next
- Further clinical data regarding the drug's effectiveness for lung cancer patients
- Additional updates on patient outcomes and accessibility following the Food and Drug Administration approval
confidence 100%Sources used for this update (4)
- www.etvbharat.com — Can Stress Actually Cause Cancer, Or Is That Just Something People Say? Oncologist Responds
- www.yahoo.com — FDA approves new drug for pancreatic cancer. Who’s eligible and how does it work?
- finance.yahoo.com — New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
- www.wbaltv.com — Routine blood testing may hold hidden clues to colorectal cancer before age 45
-
Approved Pancreatic Cancer Drug Shows Early Promise for Lung Cancer
A newly approved medication that targets advanced pancreatic cancer may also offer potential benefits for lung cancer patients, according to early study findings. The Food and Drug Administration previously authorized daraxonrasib, an oral multi-selective RAS(ON) inhibitor developed by RevMed, for adults diagnosed with metastatic pancreatic adenocarcinoma. Clinical data indicates the drug can nearly double survival rates for individuals with this form of the disease. Patients, including former University of Florida President Sasse, have credited the medication with extending their lives.
Why it matters
The Food and Drug Administration authorized daraxonrasib for patients who previously underwent at least one systemic therapy or lacked options for multiagent systemic therapy. The medication works by blocking specific proteins that drive tumor growth. Further investigation into its effectiveness against other malignancies could expand treatment options.
What is confirmed
- The Food and Drug Administration approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor developed by RevMed, for adults with metastatic pancreatic adenocarcinoma.
- Clinical data indicates the drug can nearly double survival rates for metastatic pancreatic adenocarcinoma.
- A new study suggests the pancreatic cancer drug may hold promise for lung cancer as well.
What to watch next
- Results from formal clinical trials testing daraxonrasib on lung cancer patients
- Data on whether the drug can effectively target tumor-driving proteins in other types of cancer
confidence 95%Sources used for this update (5)
- www.coloradopolitics.com — House passes stopgap funding bill with help of 176 Democrats to avoid pre-election shutdown
- abcnews.com — Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
- www.wvgazettemail.com — USS Lincoln crew hits the streets of Thai beach city after lengthy Middle East deployment
- www.news-medical.net — New study uncovers bacterial route to testosterone production
- www.news-medical.net — Tumor environments sculpt diverse natural killer cells for cancer therapies
-
FDA approves daraxonrasib for metastatic pancreatic cancer
The FDA approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma. The drug is authorized for patients who have already undergone at least one prior systemic therapy or those who are not candidates for multiagent systemic therapy. Developed by RevMed, the medication blocks proteins that drive tumor growth. Clinical data indicates the drug can nearly double survival rates for this form of cancer. Patients including former UF President Sasse have credited the pill with extending their lives.
Why it matters
Pancreatic cancer is one of the deadliest cancer forms. This approval follows a landmark clinical trial led by Dana-Farber. The drug provides a new option for patients whose cancer has spread and continued to progress despite previous treatments.
What is confirmed
- The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma.
- The medication is an oral multi-selective RAS(ON) inhibitor.
- The drug is for patients who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
- The drug is for patients whose pancreatic cancer has spread to other parts of the body and progressed despite previous treatment.
What to watch next
- Publication of full results from the Dana-Farber clinical trial
- Insurance coverage determinations for daraxonrasib
confidence 100%Sources used for this update (5)
- www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
- www.news-medical.net — FDA approves daraxonrasib for patients with metastatic pancreatic cancer
- www.denverpost.com — Federal grant cuts hit Colorado studies to make healthcare more efficient
- www.coloradopolitics.com — Trump promises retaliation for Iran attacks: ‘We’re going to hit them hard’
- www.coloradopolitics.com — Trump says communities that don’t build data centers will be ‘backwards and poor’
-
FDA Approves Rasonque Pill for Advanced Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib), a daily oral RAS inhibitor, for adults with advanced pancreatic cancer. Developed by RevMed, the medication blocks a protein that drives tumor growth. Clinical data indicates the drug can nearly double patient survival rates for one of the deadliest cancer forms. Patients including former UF President Sasse and a stage 4 patient in Maine have credited the pill with extending their lives.
Why it matters
Metastatic pancreatic cancer has historically offered patients limited treatment options and short survival windows. This approval introduces the first pill specifically designed to extend survival in these cases.
What is confirmed
- The FDA approved Rasonque for adults with advanced pancreatic cancer.
- Rasonque is a daily oral pill.
- The drug functions as a RAS inhibitor.
Still unconfirmed
- Rasonque can nearly double patient survival rates.
- Former UF President Sasse and a patient in Maine credit the drug with extending their lives.
What to watch next
- Long-term survival data from the global clinical trial.
- Insurance coverage and accessibility updates for Rasonque.
confidence 90%Sources used for this update (4)
- medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
- apnews.com — Live updates: Iran war reaches its six-month mark as Trump turns focus to increasing economic pressure
- www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
- www.coloradopolitics.com — House will vote to denounce socialism
-
FDA Approves RASONQUE for Advanced Pancreatic Cancer
The FDA approved RASONQUE (daraxonrasib) on Wednesday to treat advanced pancreatic cancer. The once-daily pill blocks a protein that drives tumor growth and has shown the ability to nearly double patient survival rates. The drug is developed by RevMed and targets one of the deadliest forms of cancer. Early reports include a patient in Maine with stage 4 cancer and former UF President Sasse, who both credit the medication with extending their lives.
Why it matters
Pancreatic cancer is notoriously difficult to treat and often has low survival rates. This approval introduces a targeted approach to managing the disease. The drug's success may position RevMed as a major player in oncology.
What is confirmed
- The FDA approved RASONQUE (daraxonrasib) on Wednesday for advanced pancreatic cancer.
- The drug is a once-daily pill that blocks a protein driving tumor growth.
- Clinical data indicates the treatment nearly doubles patient survival rates.
Still unconfirmed
- RevMed could become the next oncology titan following the Rasonque approval.
- Questions linger on the ground as RevMed prepares for the drug launch.
What to watch next
- Availability and pricing details for RASONQUE
- Long-term survival data from expanded patient groups
- Development of similar protein-blocking medicines
confidence 95%Sources used for this update (14)
- The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
- Pancreatic Cancer Action Network — FDA Approves RASONQUE™ (daraxonrasib)
- The New York Times — The Race to Develop More Medicines Like the New Pancreatic Cancer Drug
- STAT — Pharmalittle: We're reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
- Fierce Pharma — As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground
- www.forbes.com — Forbes Daily: Nvidia Beats Expectations As Data Center Business Grows
- BioSpace — RevMed could become ‘next oncology titan’ with Rasonque nod
- www.today.com — FDA Approves ‘Game-Changing’ Pancreatic Cancer Drug
- NPR — New FDA-approved drug offers hope in pancreatic cancer treatment : Here & Now Anytime
- www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
- www.usatoday.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
- www.yahoo.com — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
-
FDA Approves Daraxonrasib for Pancreatic Cancer Treatment
The FDA has approved daraxonrasib, a once-daily pill designed to treat pancreatic cancer. The drug works by blocking a protein that drives tumor growth in most cases. Clinical data indicates the treatment nearly doubles patient survival rates. This approval introduces a new approach to managing a deadly disease, with some patients, including one with stage 4 cancer in Maine, reporting that the medication is extending their lives.
Why it matters
Pancreatic cancer is known as a deadly disease with historically limited treatment options. This drug targets a specific protein fueling tumors in the vast majority of cases. The approval represents a shift in care for patients facing this diagnosis.
What is confirmed
- The FDA approved the drug daraxonrasib to treat pancreatic cancer.
- The medication is a once-daily pill.
- The drug improves survival rates for patients.
Still unconfirmed
- Patient survival rates nearly double with the use of this pill.
- The drug blocks a protein that fuels tumor growth in the vast majority of cases.
- A stage 4 cancer patient in Maine says the pill is buying him time.
What to watch next
- Publication of full clinical trial data regarding survival rate increases.
- Insurance coverage and accessibility reports for daraxonrasib.
confidence 90%Sources used for this update (8)
- WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
- The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
- Fox News — FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
- AP News — FDA approves landmark pancreatic cancer drug that’s shown to improve survival
- BBC — FDA approves breakthrough drug daraxonrasib to treat pancreatic cancer
- WGME — Stage 4 Maine cancer patient says new FDA-approved pill is buying him time
- CBS News — FDA approves new pancreatic cancer drug that could extend patients' lives
- www.boisestatepublicradio.org — FDA approves landmark pancreatic cancer drug that's shown to improve survival
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community